GlobalData on MSN
Enrolment concludes in Biohaven’s RISE3 trial for epilepsy
Topline results from RISE3 are expected in H2 2026.
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and ...
Biohaven announced a series of scientific leadership changes, including the upcoming transition of Bruce Car, Ph.D., to Chief ...
KTVX Salt Lake City on MSN
Intermountain Health doctors perform 100th surgery using brain implants to improve epilepsy symptoms
SALT LAKE CITY (ABC4) — Intermountain Health neurologists are celebrating a major surgical milestone: the 100th use of an implantable device that reduces seizure activity in patients with focal ...
Most newly diagnosed patients with focal epilepsy continued to have seizures for a year or more after starting antiseizure medications (ASMs), results from the latest Human Epilepsy Project (HEP) ...
Early detection of focal epilepsy may reduce the amount of motor vehicle accidents caused by seizures while driving. The prevalence of seizures while driving (SzWD) prior to diagnosis in people with ...
Families often preferred to remain on treatment despite the risk of vision loss. For patients with focal seizures due to tuberous sclerosis, treatment with vigabatrin may be an effective option for ...
Layla’s journey with epilepsy began when she was just six years old, though her condition didn't look like the typical ...
In focal epilepsy, seizures are generated by a localized, synchronous neuronal electrical discharge that may spread to large portions of the brain. In spite of intense research in the field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results